The invention relates to a solid pharmaceutical preparation comprising levothyroxine sodium, gelatine, citric acid and a filler. The solid pharmaceutical preparation has an improved stability.

The present invention provides pyrazoloquinazolinone and pyrroloquinazolinone derivatives of the general formula (I) and pharmaceutical compositions containing them. Moreover, the compounds of formula (I) and the compositions containing them are provided for use in the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals. These pyrazoloquinazolinone and pyrroloquinazolinone derivatives of the general formula (I) can act as modulators of nervous system receptors sensitive to glutamate, in particular as modulators of metabotropic glutamate receptors (mGluRs), which makes them particularly suitable for the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders.

The present specification provides compositions of β-endorphin and adrenocorticotropic hormone (ACTH). These compositions are useful in methods of treating disease.

The present invention provides small molecule inhibitors of BMP signaling and compositions and methods for inhibiting BMP signaling. These compounds and compositions may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds and compositions may also be used to reduce circulating levels of ApoB-100 or LDL and treat or prevent acquired or congenital hypercholesterolemia or hyperlipoproteinemia; diseases, disorders, or syndromes associated with defects in lipid absorption or metabolism; or diseases, disorders, or syndromes caused by hyperlipidemia.

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

A combination of N-acetyl-L-cysteine, selenium in the form of selenomethionine and melatonin, and a medical product or pharmaceutical composition comprising such combination, useful for the treatment of a variety of diseases and conditions is described. The combination of N-acetyl-L-cysteine, selenium in the form of selenomethionine and melatonin is also useful for cosmetic treatment of skin and as an antibacterial agent.

The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics.

The present disclosure relates to a film for oral hemostasis and wound protection and, more particularly, to a film for oral hemostasis and wound protection which, being attached to a wound area in an oral cavity, delays or prevents microbleeds and controls medicinal component release. The film provided by the present disclosure is capable of including a polyol, an alcohol and a biodegradable polymer in the state of partial swelling, thereby locally absorbing blood or pus or arresting hemorrhage. Moreover, due to its high elongation ratio, the film provided by the present disclosure is capable of maintaining its adhesive force even when having blood, saliva and pus absorbed inside an oral cavity and conveniently deforming according to the shape of a seriously corrugated local area, which causes only slight foreign body sensation even after a long period of time of attachment on to the local area. In addition, the film provided by the present disclosure includes a disintegrant which is dissolved and released by reacting with blood to form microchannels that act as paths for drug release and is capable of adjusting the amount and the size of the microchannels, thereby controlling the amount of drug release. The present disclosure doesn't require a patient to detach the film attached inside an oral cavity by hand because the adhesive layer and the backing layer dissolve entirely over time.

The present invention relates to a polypeptide binding to human serum albumin and comprising or consisting of an amino acid sequence selected from the group consisting of: (a) GVTLFVALYDY(X.sup.1)(X.sup.2)(X.sup.3)(X.sup.4)(X.sup.5) (X.sup.6)D(X.sup.7)SFHKGEKFQIL(X.sup.8)(X.sup.9)(X.sup.10)(X.sup.11)(X.sup.12)G(X.sup.13)(X.sup.14)W(X.sup.15)(X.sup.16)RSLTTG(X.sup.17)(X.sup.18)G(X.sup.19)IPSNYVAPVDSIQ (SEQ ID NO: 1), wherein (X.sup.1) is A, V, I, L, M, G, P, S, T, N, Q, C, R, H, K, D or E; (X.sup.2) is R, H, K, A, V, I, L, M, G, P, S, T, N, Q or C; (X.sup.3) is R, H, K, S, T, N, Q, C, F, Y, W, A, V, I, L, M, G or P; (X.sup.4) is S, T, N, Q, C, A, V, I, L, M, G, P, R, H, K, F, Y, W, D or E; (X.sup.5) is S, T, N, Q, C, D, E, F, Y, W, A, V, I, L, M, G, P, R, H or K; (X.sup.6) is F, Y, W, A, V, I, L, M, G, P, R, H, K, S, T, N, Q or C; (X.sup.7) is A, V, I, L, M, G, P, R, H or K; (X.sup.8) is S, T, N, Q, C, D or E; (X.sup.9) is S, T, N, Q, C, D, E, A, V, I, L, M, G, P, F, Y or W; (X.sup.10) is A, V, I, L, M, G or P; (X.sup.11) is F, Y, W, R, H or K; (X.sup.12) is S, T, N, Q, C, F, Y or W; (X.sup.13) is F, Y, W, R, H, K, S, T, N, Q, C, D, E, A, V, I, L, M, G or P; (X.sup.14) is F, Y, W, A, V, I, L, M, G or P; (X.sup.15) is D, E, A, V, I, L, M, G or P; (X.sup.16) is A, V, I, L, M, G or P; (X.sup.17) is D, E, A, V, I, L, M, G, P, R, H or K; (X.sup.18) is S, T, N, Q, C, A, V, I, L, M, G or P; (X.sup.19) is F, Y, W, S, T, N, Q or C; and (b) an amino acid sequence which is at least 90% identical to the amino acid sequence of (a), wherein the identity determination excludes amino acid positions (X.sup.1) to (X.sup.19).

The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.